Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

143.19 +0.82 (+0.58%)
Streaming Delayed Price Updated: 12:04 PM EDT, Jul 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,546,605
Open 142.28
Bid (Size) 143.17 (1)
Ask (Size) 143.20 (1)
Prev. Close 142.37
Today's Range 142.18 - 143.69
52wk Range 75.56 - 148.15
Shares Outstanding N/A
Dividend Yield 1.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Will NVO Provide Any Buying Opportunity?
Novo Nordisk A/S, a healthcare company engages in the research, development, manufacture & marketing of the pharmaceutical products worldwide. 
Via Talk Markets
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs

Performance

YTD
+40.23%
+40.23%
1 Month
+0.22%
+0.22%
3 Month
+12.34%
+12.34%
6 Month
+34.58%
+34.58%
1 Year
+82.33%
+82.33%

More News

Read More
The 7 Best Under $10 Stocks to Buy in July 2024
Via InvestorPlace
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
Via Investor's Business Daily
Looking for growth without the hefty price tag? Consider NYSE:NVO.
Via Chartmill
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Via Benzinga
Why Novo Nordisk Stock Is Slipping Today
Via The Motley Fool
MarketBeat Week in Review – 7/1 - 7/5
Via MarketBeat
Topics Economy
Exposures Interest Rates
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
Via Benzinga
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Via Benzinga
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Beyond The Numbers: 8 Analysts Discuss Novo Nordisk Stock
Via Benzinga
Is It Too Late to Buy Novo Nordisk Stock?
Via The Motley Fool
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
Via The Motley Fool
The 3 Best Healthcare Stocks to Buy in July 2024
Via InvestorPlace
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
Via Benzinga
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
Via Investor's Business Daily
The 7 Best Stocks to Buy in July 2024
Via InvestorPlace
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Via MarketBeat
Exposures Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
Via Investor's Business Daily
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
Via Investor's Business Daily
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.